Pedro Exman MD, PhD
@PedroExman
Followers
362
Following
1K
Statuses
414
👨⚕️Oncologista no @hospitalalemao-especializado em câncer de mama,👨👩👦👦pai do Alê, Gui e do Lipe, marido da Monique. ⚽️Corinthians e 🏈Patriots
São Paulo, Brasil
Joined August 2017
RT @PTarantinoMD: Simultaneous @NatureMedicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a str…
0
53
0
RT @drsarahsam: Now an option for HR+, HER2- patients. The data for T-Dxd in HER2-Low and Ultra-low is more impressive. Could be an optio…
0
13
0
0
5
0
RT @FernandoOnco: Now online Pivotal #SABCS24 summary hosted @CancerNetwrk @PTarantinoMD @matteolambe
#breastcancer
0
7
0
RT @VKaklamani: My take aways from #sabcs24: anthra beneficial for RS>31; imlunestrant active as single agent unclear what combo data means…
0
32
0
😃
@PedroExman @DanaFarberNews @OncoAlert We would like to inform you that your post has been published on Thank you for sharing
0
0
0
Just when you think there's no way to improve, the discussion comes and breaks the bank again !!! What a presentation by @Otto_DFCI ! What a discussion by Dr Sara Hurvitz !! I'm looking forward to DB09 so we can break our heads again. @OncoAlert @SABCSSanAntonio #bcsm
0
5
15
Join us at P-08-05 Real world data comparing CDK4/6 inhibitors Congrats to our last year Med Onc fellow, Dr. Betiol 👏👏 @hospitalalemao @OncoAlert #bcsm #SABCS2024
🧐 Do you like real world data? If so, .. 🚨 Join our great Med Onc fellow Dr. Betiol from Hospital Alemão Oswaldo Cruz at Poster Session to discuss RWD comparing CDK4/6 inhibitors at 1st line. P-08-05 12pm-14pm @Julhao_03 @hospitalalemao @OncoAlert #SABCS2024 #bcsm
0
6
13
RT @stolaney1: PATINA: 1L maintenance HP +ET +/- palbo in ER+ HER2+ BC n=518 72% had prior tx for early-stage dz PFS 44.3 vs 29.1 mo, H…
0
29
0
RT @IlanaSchlam: PRACTICE CHANGING findings from PATINA presented by @Otto_DFCI - n=518 HR+/HER2+ mBC - all received THP followed by HP+ET…
0
30
0
🧐 Do you like real world data? If so, .. 🚨 Join our great Med Onc fellow Dr. Betiol from Hospital Alemão Oswaldo Cruz at Poster Session to discuss RWD comparing CDK4/6 inhibitors at 1st line. P-08-05 12pm-14pm @Julhao_03 @hospitalalemao @OncoAlert #SABCS2024 #bcsm
0
2
5
Trials designed in parallel and published in sequence have made the ER+ MBC second-line landscape very complex! As always, Hal's overviews are very insightful. @DrHBurstein
@OncoAlert #bcsm #SABCS2024
0
5
9
RT @renata_bonadio: Important data presented by @matteolambe at #SABCS2024 @OncoAlert 📍Among young BRCA carriers with a history of breast…
0
9
0
RT @stolaney1: BEAUTIFUL discussion of EMBER-3 by @DrHBurstein Benefit for Imlunestrant + abemaciclib seen irrespective of ESR1m or PI3Km,…
0
8
0
RT @PTarantinoMD: The new #Halgorithm for treating HR+/HER2- metastatic breast cancer @DrHBurstein @SABCSSanAntonio @DFCI_BreastOnc #bcsm…
0
104
0
RT @stolaney1: EMBER-3 Imulen+ abema vs Imlun vs SOC ET Imlun superior to SOC ET in ESR1m, not in ITT Imlun + abema vs Imlun, PFS 9.4…
0
32
0